...we present an advanced ICC patient…As the next-generation sequencing (NGS) revealed BRAF V600E mutation in the tumor tissue, this patient was started on vemurafenib with a dosage of 720–960 mg BID and achieved 7 months progression-free survival with significant remission of clinical symptoms.